Avandia

(Rosiglitazone)

ApprovedSmall molecule

Rosiglitazone is used to help control blood sugar levels in people with type 2 diabetes by making the body more sensitive to insulin.[2] Avandia is currently approved and in use across 31 indications[4].[1]

Avandia is one of 712 small molecule programs targeting Pituitary Tumor. It is currently in Approved.

Indications

131

Total Trials

Active Trials

711

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Pituitary TumorActive, not recruiting

Metabolic DiseaseApproved

Diabetic NeuropathyApproved

Abnormal Glucose ToleranceApproved

Non-Alcoholic Fatty Liver DiseaseApproved

HIV InfectionApproved

Prediabetes SyndromeApproved

Breast CancerApproved

Dilated CardiomyopathyActive, not recruiting

Rheumatoid ArthritisApproved

Pituitary TumorPreclinical

Active, not recruiting

Metabolic DiseaseApproved

Approved

Diabetic NeuropathyApproved

Approved

Abnormal Glucose ToleranceApproved

Approved

Non-Alcoholic Fatty Liver DiseaseApproved

Approved

HIV InfectionApproved

Approved

Prediabetes SyndromeApproved

Approved

Breast CancerApproved

Approved

Dilated CardiomyopathyPreclinical

Active, not recruiting

Rheumatoid ArthritisApproved

Approved

Showing 10 of 31 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Avandia

Lexiscan

1 3

Duragesic-100

CCephalon

Preclinical

2 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 5

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 2Recruiting

Melanoma

NCT04114136

Clinical

Trials by Indication[1]

Type 2 Diabetes19 trials

BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

Completed· GSK logo

GSK·Phase 3·NCT00297063·350 enrolled

Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes

Completed·—·Phase 4·NCT00373178·100 enrolled

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

Completed· GSK logo

GSK·Phase 3·NCT00432679·149 enrolled

Show 16 more trials

Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

Completed·UUniversity of Michigan·N/A·NCT00549874·27 enrolled

AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone

Completed· GSK logo

GSK·Phase 4·NCT00333723·245 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00318422·1,041 enrolled

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

Completed· GSK logo

GSK·Phase 3·NCT00523913·70 enrolled

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

Completed·EEmory University·Phase 4·NCT00738023·36 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00333151·576 enrolled

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

Completed·WWashington University School of Medicine·N/A·NCT00577590·78 enrolled

Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00680745·597 enrolled

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Terminated· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00343980·363 enrolled

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

Completed· GSK logo

GSK·Phase 4·NCT00679939·226 enrolled

Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

Completed· GSK logo

GSK··NCT00995995·7,641 enrolled

Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Terminated· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00348712·301 enrolled

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

Terminated· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00427154·227 enrolled

Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes

Completed·TTurku University Hospital·Phase 4·NCT02526615·48 enrolled

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

Completed·WWellstat Therapeutics·Phase 2·NCT00110851·90 enrolled

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00081328·699 enrolled

Type 2 Diabetes Mellitus7 trials

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

Completed· Takeda logo

Takeda·Phase 3·NCT00331487·719 enrolled

Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 4·NCT00306176·100 enrolled

A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients

Completed· GSK logo

GSK·Phase 3·NCT00349427·256 enrolled

Show 4 more trials

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00135330·137 enrolled

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Completed· GSK logo

GSK·Phase 4·NCT00329225·630 enrolled

South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus

Completed·OOdense University Hospital·Phase 4·NCT00121966·400 enrolled

Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus

Completed· GSK logo

GSK·Phase 3·NCT00231387·60 enrolled

Insulin resistance6 trials

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00015626·300 enrolled

Rosiglitazone and Insulin Resistance in Renally Impaired Patients

Terminated·LLeiden University Medical Center·Phase 3·NCT00452166·30 enrolled

Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00746174·24 enrolled

Show 3 more trials

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT00130286·77 enrolled

Insulin Resistance in Patients With Mood Disorder

Completed·SStanford University·N/A·NCT00242619·12 enrolled

Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes

Completed· GSK logo

GSK·Phase 4·NCT00306644·556 enrolled

Mild to Moderate Alzheimer's Disease4 trials

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

Completed· GSK logo

GSK·Phase 3·NCT00428090·862 enrolled

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

Completed· GSK logo

GSK·Phase 3·NCT00348140·1,468 enrolled

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

Completed· GSK logo

GSK·N/A·NCT00348309·1,496 enrolled

Show 1 more trial

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

Completed· GSK logo

GSK·Phase 2·NCT00381238·33 enrolled

Treatment4 trials

Effect of Thiazolidinedione Treatment Vascular Risk Markers

Completed·UUniversity of Arkansas·Phase 4·NCT00571506·25 enrolled

The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells

Completed·UUniversity of Aarhus·Phase 2·NCT00609362·57 enrolled

Preferred Treatment of Type 1.5 Diabetes

Completed·UUniversity of Washington·N/A·NCT00194896·64 enrolled

Show 1 more trial

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00295633·565 enrolled

68 more indications

Interaction3 trials

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

Completed· GSK logo

GSK·Phase 1·NCT00964106·87 enrolled

Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00785213·23 enrolled

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Completed· GSK logo

GSK·Phase 1·NCT00511823·16 enrolled

Atherosclerosis3 trials

The Impact of Rosiglitazone on Regression of Atherosclerosis

Suspended·NNational Taiwan University Hospital·N/A·NCT00166803·60 enrolled

Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?

Unknown status·HHospital Authority, Hong Kong·N/A·NCT00516880·160 enrolled

The Study of Atherosclerosis With Ramipril and Rosiglitazone

Completed·—·Phase 3·NCT00140647·1,200 enrolled

Tics3 trials

Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects

Completed·VVIVUS LLC·Phase 1·NCT01415128·60 enrolled

Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

Withdrawn·UUniversity of Glasgow·Phase 4·NCT00225342·60 enrolled

Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.

Completed· GSK logo

GSK·Phase 4·NCT00306696·388 enrolled

Asthma3 trials

Rosiglitazone Versus Theophylline in Asthmatic Smokers

Completed·UUniversity of Glasgow·Phase 2/3·NCT00119496·79 enrolled

The Effect Of AVANDIA On The Late Asthmatic Response

Completed· GSK logo

GSK·Phase 1·NCT00318630·26 enrolled

The Use of Rosiglitazone to Treat Asthma

Completed·—·Phase 2·NCT00614874·16 enrolled

Malaria2 trials

Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

Completed·MMahidol University·Phase 1/2·NCT00149383·140 enrolled

Rosiglitazone Adjunctive Therapy for Severe Malaria in Children

Completed·CCentro de Investigacao em Saude de Manhica·N/A·NCT02694874·210 enrolled

Combination Therapy2 trials

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00350779·262 enrolled

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

Completed· Sanofi logo

Sanofi·Phase 4·NCT00358124·220 enrolled

Metformin2 trials

Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

Terminated·SSolvay Pharmaceuticals·Phase 3·NCT00361868·88 enrolled

Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin

Completed· GSK logo

GSK·Phase 4·NCT00501020·750 enrolled

Diabetes2 trials

To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients

Completed·UUniversiti Sains Malaysia·Phase 3·NCT00489229·66 enrolled

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes

Completed· GSK logo

GSK·Phase 3·NCT00379769·4,447 enrolled

Polycystic Ovary Syndrome2 trials

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

Completed·SSilva Arslanian·Phase 4·NCT00640224·65 enrolled

Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome

Completed·JJean-Patrice Baillargeon·N/A·NCT01019356·52 enrolled

Alzheimer's Disease2 trials

Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)

Completed· GSK logo

GSK·Phase 1·NCT00688207·14 enrolled

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

Completed· GSK logo

GSK·Phase 2·NCT00265148·80 enrolled

Ulcerative Colitis2 trials

A Trial of Rosiglitazone for Ulcerative Colitis

Completed·JJames Lewis·Phase 2·NCT00065065·105 enrolled

Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Unknown status·HHerlev Hospital·Phase 1/2·NCT00309660·20 enrolled

Metabolic Syndrome2 trials

11ß-HSD1 and Metabolic Syndrome

Completed·—·Phase 2·NCT00370305·24 enrolled

Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

Completed·UUniversity of Colorado, Denver·Phase 4·NCT00364221

Endometriosis2 trials

Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

Withdrawn·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2/3·NCT00121953

Use of Rosiglitazone in the Treatment of Endometriosis

Terminated·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00115661·25 enrolled

Lip2 trials

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)

Terminated·AAhmad Slim·Phase 4·NCT00819910·41 enrolled

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

Completed·—·Phase 4·NCT00953498·40 enrolled

Impaired glucose tolerance2 trials

Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance

Unknown status·—·Phase 4·NCT00733174·60 enrolled

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Completed·YYale University·N/A·NCT00413335·21 enrolled

Albuminuria1 trial

Rosiglitazone on Microalbuminuria in Type 2 Diabetics

Completed· GSK logo

GSK·Phase 3·NCT00500955·336 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Completed· Roche logo

Roche·Phase 1·NCT01209143·52 enrolled

Weight Gain1 trial

Rosiglitazone-Induced Weight Gain

Terminated·SStanford University·N/A·NCT00225225·45 enrolled

Vitamin D1 trial

Thiazolidinedione Intervention With Vitamin D Evaluation

Terminated· GSK logo

GSK·Phase 4·NCT00879970·1,332 enrolled

Adult Subject1 trial

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

Completed· GSK logo

GSK·Phase 1·NCT00615212·23 enrolled

Cholesterol1 trial

A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs

Completed·UUniversity of Chicago·Phase 2/3·NCT00831129·53 enrolled

Neuropathy1 trial

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

Completed· GSK logo

GSK·Phase 3·NCT00422955·36 enrolled

Randomized1 trial

Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone

Terminated· Pfizer logo

Pfizer·N/A·NCT00282945·29 enrolled

Completed·NNorthwell Health·Phase 1·NCT00193648·21 enrolled

Cognition1 trial

Rosiglitazone Effects on Cognition for Adults in Later Life

Unknown status·UUniversity of Washington·Phase 2·NCT00242593·120 enrolled

Memory1 trial

Insulin, Neurogenetics and Memory in Alzheimer's Disease

Completed·UUS Department of Veterans Affairs·Phase 2·NCT00018382

Adenoma1 trial

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Unknown status·ZZhaoyun Zhang·N/A·NCT03309319·24 enrolled

Women1 trial

Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women

Completed·—·Phase 4·NCT00440375·82 enrolled

Critical Illness1 trial

Effect of Rosiglitazone on ADMA in Critical Illness

Unknown status·AAmsterdam UMC, location VUmc·Phase 3·NCT00409097·30 enrolled

Atherosclerotic Plaque1 trial

Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque

Completed·—·N/A·NCT00636766·300 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Insulin Resistance in Non-alcoholic Fatty Liver Disease

Terminated·UUS Department of Veterans Affairs·N/A·NCT00252499·13 enrolled

Chronic Kidney Disease1 trial

Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease

Withdrawn·LLeiden University Medical Center·Phase 2/3·NCT00169923·200 enrolled

Glucose intolerance1 trial

Prevention of Corticosteroid-induced Glucose Intolerance

Unknown status·HHadassah Medical Organization·Phase 3·NCT00240604·100 enrolled

Type 2 Diabetic Patients1 trial

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

Completed·SSt. Paul Heart Clinic·Phase 4·NCT00123643·36 enrolled

Hyperlipidemia1 trial

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00006493

Adipokines1 trial

Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study

Completed·—·N/A·NCT00486187·103 enrolled

Efficacy and Safety1 trial

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

Completed· GSK logo

GSK·Phase 4·NCT00044460·142 enrolled

ISS1 trial

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

Completed·UUniversity of Massachusetts, Worcester·Phase 2·NCT01150981·35 enrolled

Adolescent1 trial

Rosiglitazone and Insulin in T1DM Adolescents

Completed·TThe University of New South Wales·Phase 4·NCT00372086·32 enrolled

Cardiovascular1 trial

Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00424762·150 enrolled

Plaque1 trial

Rosiglitazone Plaque Study

Unknown status·RRoyal Brompton & Harefield NHS Foundation Trust·Phase 3·NCT00123227·60 enrolled

Monotherapy1 trial

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Completed· GSK logo

GSK·Phase 3·NCT00279045·4,426 enrolled

Pilot Study1 trial

Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study

Withdrawn·IImperial College London··NCT00481429

Weight loss1 trial

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

Completed·SStanford University·N/A·NCT00186537·47 enrolled

Metabolism1 trial

Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment

Completed·MMassachusetts General Hospital·Phase 4·NCT00337350·20 enrolled

Dyslipidemia1 trial

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

Completed·FFoundation Research, Florida·Phase 4·NCT00304993·30 enrolled

Ischemia1 trial

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

Completed·RRadboud University Medical Center·Phase 2·NCT00405015·13 enrolled

Medication1 trial

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

Completed·—·Phase 3·NCT00095654·5,000 enrolled

Relapse1 trial

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

Completed·—·Phase 4·NCT00207402·34 enrolled

Longevity1 trial

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

Terminated·MMedstar Health Research Institute·Phase 3·NCT00465296·200 enrolled

Chronic Stable Angina1 trial

Rosiglitazone Versus Placebo in Chronic Stable Angina

Terminated·UUniversity of Glasgow·Phase 4·NCT00225355·80 enrolled

Genetic Polymorphism1 trial

Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response

Completed·—··NCT00501488·42 enrolled

Non-Alcoholic Steatohepatitis1 trial

A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis

Completed·AAssociation pour la Recherche sur les Maladies Hépatiques Virales·Phase 2·NCT00492700·63 enrolled

Diabetes Mellitus1 trial

Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)

Completed·VVA Office of Research and Development·Phase 3·NCT00032487·1,791 enrolled

NASH1 trial

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Terminated·SSeoul St. Mary's Hospital·Phase 4·NCT01406704·26 enrolled

Solid Tumors1 trial

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Completed·EExelixis·Phase 1·NCT01100619·40 enrolled

PreDiabetes1 trial

Physical Exercise Versus Rosiglitazone in CAD and Prediabetes

Completed·UUniversity of Leipzig·Phase 4·NCT00675740·45 enrolled

Kidney Transplant1 trial

Metabolic and Renal Effects of Rosiglitazone in Kidney Transplant

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT00309309·10 enrolled

ESS1 trial

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

Completed·VVanda Pharmaceuticals·Phase 1·NCT01402076·24 enrolled

Endothelial Dysfunction1 trial

Endothelial Dysfunction as a Risk Factor in HIV Study

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00039663·75 enrolled

Acute Lymphoblastic Leukemia1 trial

Identification of Null Allelic Variant of CYP2C8 In A Korean Population

Completed·IInje University·Phase 1·NCT01872780·11 enrolled

Prostate Cancer1 trial

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Completed·MMassachusetts General Hospital·Phase 3·NCT00182052·100 enrolled

Diabetic Nephropathy1 trial

Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

Completed·TTechnische Universität Dresden·N/A·NCT00324675·28 enrolled

Vascular Disease1 trial

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Completed·UUS Department of Veterans Affairs··NCT00256646·298 enrolled

Melanoma1 trial

A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies

Recruiting·DDan Zandberg·Phase 2·NCT04114136·72 enrolled

Unspecified5 trials

BAY73-4506 Probe Substrate Study

Completed· Bayer logo

Bayer·Phase 1·NCT01287598·41 enrolled

Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.

Completed·TTechnische Universität Dresden·N/A·NCT00154011·24 enrolled

Effect of Rosiglitazone

Completed·UUniversity Hospital, Montpellier·N/A·NCT00285142·12 enrolled

Show 2 more trials

Gene Regulation by Thiazolidinediones

Completed·JJames Lewis·Phase 4·NCT00567593·12 enrolled

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Completed·—·Phase 4·NCT00522470

Regulatory

FDA Approval Timeline[5]

May 25, 1999

AVANDIA

NDA NDA021071

Sources

References

[1]
ClinicalTrials.gov — 131 trial records for Rosiglitazone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Avandia drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Rosiglitazone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Rosiglitazone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021071). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Peroxisome Proliferator-Activated Receptor Gamma Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Jazz Pharmaceuticals

Avandia

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Type 2 Diabetes19 trials

Type 2 Diabetes Mellitus7 trials

Insulin resistance6 trials

Mild to Moderate Alzheimer's Disease4 trials

Treatment4 trials

Interaction3 trials

Atherosclerosis3 trials

Tics3 trials

Asthma3 trials

Malaria2 trials

Combination Therapy2 trials

Metformin2 trials

Diabetes2 trials

Polycystic Ovary Syndrome2 trials

Alzheimer's Disease2 trials

Ulcerative Colitis2 trials

Metabolic Syndrome2 trials

Endometriosis2 trials

Lip2 trials

Impaired glucose tolerance2 trials

Albuminuria1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Weight Gain1 trial

Vitamin D1 trial

Adult Subject1 trial

Cholesterol1 trial

Neuropathy1 trial

Randomized1 trial

Atrophy1 trial

Hypertriglyceridemia1 trial

Focal Segmental Glomerulosclerosis1 trial

Cognition1 trial

Memory1 trial

Adenoma1 trial

Women1 trial

Critical Illness1 trial

Atherosclerotic Plaque1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Chronic Kidney Disease1 trial

Glucose intolerance1 trial

Type 2 Diabetic Patients1 trial

Hyperlipidemia1 trial

Adipokines1 trial

Efficacy and Safety1 trial

ISS1 trial

Adolescent1 trial

Cardiovascular1 trial

Plaque1 trial

Monotherapy1 trial

Pilot Study1 trial

Weight loss1 trial

Metabolism1 trial

Dyslipidemia1 trial

Ischemia1 trial

Medication1 trial

Relapse1 trial

Longevity1 trial

Chronic Stable Angina1 trial

Genetic Polymorphism1 trial

Non-Alcoholic Steatohepatitis1 trial

Diabetes Mellitus1 trial

NASH1 trial

Solid Tumors1 trial

PreDiabetes1 trial

Kidney Transplant1 trial

ESS1 trial

Endothelial Dysfunction1 trial

Acute Lymphoblastic Leukemia1 trial

Prostate Cancer1 trial

Diabetic Nephropathy1 trial

Vascular Disease1 trial

Melanoma1 trial

Unspecified5 trials

FDA Approval Timeline[5]